Acquisitions - Additional Information (Details) - USD ($)						1 Months Ended	2 Months Ended	3 Months Ended		5 Months Ended	6 Months Ended		9 Months Ended
	Mar. 01, 2022	Feb. 09, 2022	Dec. 31, 2021	Nov. 02, 2021	Apr. 02, 2021	Dec. 31, 2021	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Nov. 01, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 593,017,000			$ 593,017,000	$ 593,017,000	$ 600,974,000		$ 600,974,000	$ 600,974,000		$ 593,017,000		$ 522,814,000
Net revenue								559,355,000	$ 535,075,000		1,056,988,000	$ 1,028,180,000
Operating (loss) income								(198,618,000)	67,119,000		(175,313,000)	113,026,000
Intangible assets acquired									73,800,000			73,800,000
Intangible assets			1,256,412,000			1,256,412,000	1,256,412,000	1,374,671,000		1,374,671,000	1,374,671,000		1,256,412,000
Specialty
Business Acquisition [Line Items]
Goodwill			363,900,000			363,900,000	363,900,000	366,300,000		$ 366,300,000	366,300,000		363,900,000
Net revenue								$ 97,001,000	88,635,000		$ 182,087,000	184,566,000
Marketed product rights
Business Acquisition [Line Items]
Intangible assets acquired					$ 83,815,000
In-process research and development
Business Acquisition [Line Items]
Intangible assets acquired												44,300,000
Puniska Healthcare Pvt Ltd
Business Acquisition [Line Items]
Goodwill														$ 30,091,000
Definitive acquisition agreement amount				$ 93,000,000
Consideration paid in cash on hand	$ 1,700,000		$ 14,162,000	$ 72,880,000
Voting interest acquired (percent)	26.00%			74.00%				26.00%		26.00%	26.00%
Acquired non-controlling interest, non-public subsidiary						$ 4,300,000
Acquisition, transaction costs								$ 0			$ 0
Total consideration, net of cash acquired							$ 87,042,000
Kashiv Specialty Pharmaceuticals, LLC
Business Acquisition [Line Items]
Goodwill					43,530,000
Consideration paid in cash on hand					$ 100,100,000
Voting interest acquired (percent)					98.00%
Acquisition, transaction costs								0	$ 2,000,000		0	$ 3,100,000
Total consideration, net of cash acquired					$ 104,500,000								$ 103,122,000
Working capital costs					4,400,000
Intangible assets					56,400,000
Kashiv Specialty Pharmaceuticals, LLC | Generics
Business Acquisition [Line Items]
Goodwill					40,800,000
Kashiv Specialty Pharmaceuticals, LLC | Specialty
Business Acquisition [Line Items]
Goodwill					2,700,000
Kashiv Specialty Pharmaceuticals, LLC | Marketed product rights
Business Acquisition [Line Items]
Intangible assets acquired					29,400,000
Kashiv Specialty Pharmaceuticals, LLC | In-process research and development
Business Acquisition [Line Items]
Intangible assets					27,000,000
Saol Baclofen Franchise Acquisition | Generics
Business Acquisition [Line Items]
Goodwill					5,200,000
Saol Baclofen Franchise Acquisition | Specialty
Business Acquisition [Line Items]
Goodwill					$ 2,400,000
Saol Baclofen Franchise Acquisition
Business Acquisition [Line Items]
Payment for asset acquisition		$ 84,714,000
Asset acquisition, inventory acquired		$ 1,100,000
Asset acquisition, transaction cost								0			$ 100,000
Net revenue								6,300,000		$ 9,300,000
Operating (loss) income								$ (1,900,000)		$ (2,000,000)